CLRB Cellectar Biosciences, Inc. Stock Quote

CLRB [NASD]

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	0.40%	Shs Outstand	50.50M	Perf Week	-4.05%
Market Cap	70.70M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	65.99%	Shs Float	40.70M	Perf Month	-29.35%
Income	-15.10M	PEG	-	EPS next Q	-0.10	Inst Own	45.70%	Short Float	5.22%	Perf Quarter	-30.73%
Sales	-	P/S	-	EPS this Y	58.50%	Inst Trans	212.43%	Short Ratio	1.17	Perf Half Y	12.70%
Book/sh	1.17	P/B	1.21	EPS next Y	-9.10%	ROA	-54.00%	Target Price	-	Perf Year	-5.33%
Cash/sh	1.15	P/C	1.24	EPS next 5Y	-	ROE	-83.00%	52W Range	1.01 - 2.98	Perf YTD	-31.73%
Dividend	-	P/FCF	-	EPS past 5Y	59.50%	ROI	-	52W High	-52.35%	Beta	1.63
Dividend %	-	Quick Ratio	16.30	Sales past 5Y	-	Gross Margin	-	52W Low	40.59%	ATR	0.11
Employees	11	Current Ratio	16.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.82	Volatility	6.49% 7.07%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	66.10%	Profit Margin	-	Rel Volume	0.24	Prev Close	1.40
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 02 BMO	Payout	-	Avg Volume	1.81M	Price	1.42
Recom	1.60	SMA20	-11.69%	SMA50	-25.17%	SMA200	-11.13%	Volume	428,433	Change	1.43%

Jul-01-20

Initiated

Oppenheimer

Outperform

Jan-21-20

Resumed

ROTH Capital

Buy

$10

Sep-13-19

Initiated

ROTH Capital

Buy

Dec-21-16

Initiated

Ladenburg Thalmann

Buy

$2.70

Mar-28-21 04:29AM	Are Insiders Buying Cellectar Biosciences, Inc. (NASDAQ:CLRB) Stock? Simply Wall St.
Mar-11-21 08:30AM	Cellectar to Participate at Upcoming Institutional Investor Conferences GlobeNewswire +8.52%
Mar-09-21 09:00AM	Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates GlobeNewswire +5.20%
Mar-05-21 08:30AM	Cellectar to Participate at Upcoming Institutional Investor Conferences GlobeNewswire
Mar-02-21 08:30AM	Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update GlobeNewswire +5.24%
Feb-10-21 08:30AM	Cellectar to Present at BIO CEO & Investor Digital Conference GlobeNewswire
Jan-27-21 08:30AM	Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstroms Macroglobulinemia GlobeNewswire
Jan-12-21 09:09AM	Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax Zacks
08:30AM	Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstroms Macroglobulinemia GlobeNewswire
Dec-28-20 04:05PM	Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement GlobeNewswire -5.91%
Dec-23-20 08:39AM	Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement GlobeNewswire -25.99%
Dec-22-20 05:28PM	Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement GlobeNewswire
Dec-06-20 02:12AM	We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully Simply Wall St.
Dec-01-20 11:35AM	These 2 Strong Buy Penny Stocks Could Go Boom, Says Roth Capital TipRanks +20.24%
Nov-27-20 04:13PM	Is Cellectar Biosciences (CLRB) A Good Stock To Buy According To Hedge Funds? Insider Monkey
Nov-09-20 08:44AM	Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update GlobeNewswire
Nov-05-20 09:00AM	Cellectar Biosciences CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors GlobeNewswire
Sep-10-20 08:00AM	Cellectar Biosciences to Present at Two Upcoming Investor Conferences GlobeNewswire
Sep-09-20 08:00AM	Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients GlobeNewswire +9.43%
Aug-17-20 10:01AM	Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA GlobeNewswire
Aug-10-20 08:00AM	Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update GlobeNewswire
Aug-04-20 08:00AM	Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting GlobeNewswire -6.04%
Jul-29-20 03:31PM	2 Strong Buy Healthcare Stocks That Could Be the Next M&A Target TipRanks
Jul-21-20 08:00AM	Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting GlobeNewswire
Jul-01-20 08:00AM	Cellectar Appoints Dr. John Friend as Chief Medical Officer GlobeNewswire
Jun-11-20 08:30AM	Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles GlobeNewswire -10.08%
Jun-09-20 06:33AM	Trade Alert: The Chief Business Officer Of Cellectar Biosciences, Inc. (NASDAQ:CLRB), Jarrod Longcor, Has Just Spent US$75k Buying 893% More Shares Simply Wall St. +5.08%
Jun-05-20 04:01PM	Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering GlobeNewswire
Jun-03-20 09:00AM	Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering GlobeNewswire -21.97%
Jun-01-20 08:00AM	Cellectar Granted SME Status by the European Medicines Agency GlobeNewswire -5.49%
May-28-20 10:10AM	Heres How Hedge Funds Traded Cellectar Biosciences, Inc. (CLRB) During The Crash Insider Monkey
May-27-20 10:56AM	Company News for May 27, 2020 Zacks -6.62%
May-26-20 07:45AM	Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstroms Macroglobulinemia GlobeNewswire +7.09%
May-14-20 08:00AM	Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131 GlobeNewswire
May-07-20 08:15AM	Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update GlobeNewswire
Apr-16-20 07:04AM	Here's Why We're A Bit Worried About Cellectar Biosciences's (NASDAQ:CLRB) Cash Burn Situation Simply Wall St. -8.27%
Mar-09-20 08:00AM	Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update GlobeNewswire -8.33%
Feb-19-20 08:00AM	Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study GlobeNewswire -15.14%
Jan-17-20 06:41AM	Should You Be Concerned About Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) Historical Volatility? Simply Wall St.
Jan-09-20 08:00AM	Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020 GlobeNewswire
Jan-07-20 08:00AM	Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer GlobeNewswire
Jan-06-20 08:00AM	Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL) GlobeNewswire +6.96%
Dec-19-19 08:00AM	Cellectar Biosciences to Present at Biotech Showcase 2020 GlobeNewswire +5.91%
Dec-16-19 08:00AM	Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study GlobeNewswire
Dec-13-19 08:31AM	Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium GlobeNewswire
Dec-09-19 08:30AM	Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference GlobeNewswire
Dec-02-19 08:30AM	Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference GlobeNewswire +16.93%
Nov-12-19 08:00AM	Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update GlobeNewswire -15.39%
Oct-30-19 08:00AM	Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference GlobeNewswire
Oct-19-19 09:44AM	Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth? Simply Wall St.
Oct-17-19 08:00AM	Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston GlobeNewswire
Oct-15-19 08:00AM	Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology GlobeNewswire -6.88%
Oct-08-19 08:00AM	Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology GlobeNewswire
Sep-30-19 08:30AM	Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress GlobeNewswire
Sep-24-19 08:00AM	Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma GlobeNewswire -6.72%
Sep-19-19 08:30AM	Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire
Sep-16-19 08:30AM	Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma GlobeNewswire
Sep-10-19 08:00AM	Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019 GlobeNewswire
Sep-04-19 08:00AM	Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop GlobeNewswire
Aug-20-19 12:37PM	Can We See Significant Institutional Ownership On The Cellectar Biosciences, Inc. (NASDAQ:CLRB) Share Register? Simply Wall St.
Aug-15-19 08:30AM	Cellectar Appoints Dov Elefant as Chief Financial Officer GlobeNewswire
Aug-14-19 08:30AM	CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study GlobeNewswire
Aug-12-19 08:00AM	Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update GlobeNewswire
Jul-09-19 08:30AM	Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma GlobeNewswire
May-21-19 08:30AM	Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131 GlobeNewswire +5.91%
May-20-19 04:10PM	Cellectar Biosciences Announces Closing of $10.0 Million Financing GlobeNewswire -7.00%
May-18-19 07:15AM	5 Biotech Stocks to Watch in the Second Half of 2019 ETF Trends
May-16-19 08:52AM	Cellectar Biosciences Announces $10.0 Million Financing GlobeNewswire -22.70%
May-15-19 08:30AM	CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma GlobeNewswire +23.68%
May-13-19 08:00AM	Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma GlobeNewswire
May-06-19 08:00AM	Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update GlobeNewswire
May-02-19 02:18PM	5 Biotech Stocks With Near-Term Catalysts Ahead Benzinga
Apr-29-19 10:20AM	Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Apr-10-19 01:40PM	5 Oncology Companies That Are Set to Run GuruFocus.com
Mar-19-19 08:30AM	FDA Grants Exemption to Import Alert for Cellectars CLR 131 in Pediatric and Adolescent Patients GlobeNewswire
Feb-26-19 08:30AM	Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update GlobeNewswire
Feb-25-19 08:30AM	Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131 GlobeNewswire
Feb-05-19 08:30AM	Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference GlobeNewswire
Jan-23-19 08:00AM	Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets Fifteenth Annual Investor Conference GlobeNewswire -5.83%
Jan-22-19 02:15PM	What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)? Simply Wall St.
Jan-07-19 08:30AM	Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma GlobeNewswire +8.14%
Jan-03-19 08:30AM	Cellectar Biosciences to Present at the Biotech Showcase GlobeNewswire
Dec-11-18 08:30AM	Cellectar Granted Japanese Patent for CLR 131 GlobeNewswire
Dec-04-18 08:30AM	Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma GlobeNewswire
Nov-21-18 02:53PM	Analysts Take Action on Health Care Stocks GuruFocus.com +8.84%
Nov-13-18 08:30AM	Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-12-18 08:30AM	Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies GlobeNewswire
Oct-02-18 08:00AM	Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma GlobeNewswire +12.16%
Sep-27-18 08:30AM	Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire -8.36%
08:00AM	Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences ACCESSWIRE
Sep-25-18 08:30AM	Cellectars CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma GlobeNewswire
Sep-24-18 08:00AM	Cellectar Biosciences Provides an Update on the FDA Import Alert GlobeNewswire
Sep-17-18 08:43AM	Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer MarketWatch
08:30AM	FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences CLR 131 for the Treatment of Osteosarcoma GlobeNewswire
Aug-29-18 08:30AM	Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-20-18 08:30AM	Fractionated Dosing Improves Tolerability and Safety of Cellectars CLR 131 in R/R Multiple Myeloma Patients GlobeNewswire -6.67%
Aug-13-18 09:25AM	Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:00AM	Cellectars CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewings Sarcoma GlobeNewswire
Aug-10-18 08:00AM	Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update GlobeNewswire -8.65%
Aug-01-18 08:30AM	Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate GlobeNewswire

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CARUSO JAMES V	President and CEO	Mar 04	Buy	1.70	5,100	8,659	86,401	Mar 05 05:45 PM
Longcor Jarrod	Chief Business Officer	Dec 28	Buy	1.35	29,630	40,000	102,148	Dec 28 04:31 PM
CARUSO JAMES V	President and CEO	Dec 28	Buy	1.35	37,037	50,000	81,301	Dec 28 04:31 PM
Elefant Dov	Chief Financial Officer	Dec 28	Buy	1.35	7,407	9,999	11,755	Dec 28 04:30 PM
Elefant Dov	Chief Financial Officer	Jun 05	Buy	1.15	4,348	4,978	4,348	Jun 08 04:08 PM
Longcor Jarrod	Chief Business Officer	Jun 05	Buy	1.15	65,218	74,675	72,518	Jun 08 04:08 PM
CARUSO JAMES V	President and CEO	Jun 05	Buy	1.15	21,740	24,892	44,264	Jun 08 04:07 PM
HILL STEPHEN A	Director	Jun 04	Buy	1.08	18,000	19,438	18,000	Jun 08 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience